CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A).

Mar 28, 2025 · CIP2A (Cellular Inhibitor Of PP2A) is a Protein Coding gene. Diseases associated with CIP2A include Prostate Cancer and Gastric Cancer. Among its related pathways are DNA Damage and Netrin-UNC5B signaling pathway. An important paralog of this gene is CCDC57.

Jul 16, 2022 · Here, we identify CIP2A as a TOPBP1-interacting protein that regulates TOPBP1 localization specifically in mitosis. Cells lacking CIP2A display increased radio-sensitivity, micronuclei...

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a characterized human oncoprotein that is able to promote cancer cells proliferation, anchorage-independent cell growth and resistance to apoptosis.

Jan 1, 2024 · CIP2A (cancerous inhibitor of PP2A) coordinately controls the essential characteristics of cancer cells such as protein phosphorylation, mitosis, and the DNA damage response. CIP2A allows cell-cycle progression under DNA damage by dampening the G2/M checkpoint, and protects the chromosomal integrity of DNA-damaged mitotic cells.

Dec 1, 2017 · CIP2A is an endogenous PP2A-interacting protein of human cancer cells that interacts directly with c-Myc and hinders the function of PP2A toward c-Myc S62 induction and therefore stabilizes c-Myc protein. CIP2A stimulates anchorage-independent cell growth and requires for the malignant cellular growth.

Feb 28, 2023 · Here, we report molecular level details and structural mechanisms of PP2A-B56α inhibition by an oncoprotein CIP2A. Upon direct binding to PP2A-B56α trimer, CIP2A displaces the PP2A-A subunit...

Feb 6, 2024 · CIP2A bound to pyruvate kinase M2 (PKM2) and induced the formation of PKM2 tetramer, with serine 287 as a novel phosphorylation site essential for PKM2 dimer-tetramer switching.

Studies have confirmed that CIP2A is an essential gene in BRCA1 and BRCA2 mutant cells, finding that the CIP2A-TOPBP1 axis can protect chromosome stability, which is a synthetic lethal target for BRCA mutant cancer (Adam et al., 2021).

Feb 8, 2025 · CIP2A is a major determinant mediating bortezomib-induced apoptosis in triple negative breast cancer cells. CIP2A may be useful as a therapeutic biomarker for predicting clinical response to erlotinib in hepatocellular carcinoma treatment. CIP2A overexpression is associated with ovarian cancer.